Grail Inc’s Earnings Call Balances Momentum and Risk

Grail Inc ((GRAL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Grail Inc’s latest earnings call struck a cautiously optimistic tone, balancing strong commercial and regulatory progress against meaningful clinical and financial uncertainties. Management highlighted robust test adoption, growing revenues, and a solid cash runway, while acknowledging the missed primary endpoint in the flagship NHS‑Galleri trial and ongoing operating losses.

NHS‑Galleri Top‑Line Shows Stage IV Reduction

Top‑line data from the NHS‑Galleri study pointed to a meaningful reduction of more than 20% in Stage IV cancer diagnoses in rounds two and three for a prespecified set of 12 lethal cancers. The trial also showed higher detection of Stage I and II cancers, a roughly fourfold improvement in overall cancer detection versus standard care, fewer emergency presentations, and no serious safety issues among about 70,000 participants.

PATHFINDER 2 Underscores Clinical Consistency

Management emphasized that full results from the 35,000‑participant PATHFINDER 2 study were consistent with data previously shared for the first 25,000 patients. This consistency supports the performance profile used in Galleri’s regulatory package and strengthens the argument that the test behaves reliably across large, real‑world screening populations.

PMA Submission Marks Regulatory Milestone

Grail has now completed its Premarket Approval submission to the FDA for Galleri, with the final module filed at the end of January. The test already holds Breakthrough Device status, and the company expects roughly a 12‑month review period, making the coming year pivotal for potential U.S. regulatory clearance of its multi‑cancer early detection assay.

Commercial Growth in Volume and Revenue

Galleri’s U.S. commercial trajectory continued upward, with test volumes rising 36% in 2025 to more than 185,000 tests and revenue climbing 26% to $136.8 million. Total company revenue reached $147.2 million, up 17% year over year, while fourth‑quarter revenue grew 14% to $43.6 million as the firm sold over 57,000 tests in the quarter and nearly half a million since launch.

Prescriber Base Expands with Go‑to‑Market Push

The number of providers ordering Galleri expanded to about 17,000, reflecting 30% year‑over‑year growth and broadening clinical adoption. To capitalize on this momentum, Grail plans to enlarge its field sales and medical teams, aiming to deepen penetration among existing clinicians and reach new health systems and specialty practices.

Medicare Coverage Pathway Emerges

Investors heard that recently enacted federal legislation has created a specific Medicare coverage pathway for FDA‑approved multi‑cancer early detection tests. While not an immediate reimbursement decision for Galleri, this legal framework is a structural positive that could ease future coverage decisions once regulatory approval and supporting outcomes data are in place.

Unit Economics and Loss Profile Improving

Non‑GAAP adjusted gross profit reached $23.1 million in the fourth quarter, up 29% year over year, and $73.6 million for 2025, up 27%. Adjusted EBITDA loss narrowed to $71.8 million in Q4 and $320.6 million for the full year, improvements of 15% and 34% respectively, as management reiterated a long‑term gross margin goal in the 50% to 60% range at scale.

Cash Runway Supports Long‑Term Plan

Grail closed 2025 with $904.4 million in cash, giving the company a projected runway into 2030 even as it invests in trials, commercialization, and regulatory activities. This balance sheet strength is a critical buffer while the business works toward profitability and navigates upcoming regulatory and reimbursement decisions.

NHS‑Galleri Misses Primary Endpoint

Despite promising Stage IV data, the NHS‑Galleri trial did not achieve its primary endpoint of a statistically significant reduction in combined Stage III and IV cancers. The shortfall on this composite measure tempers the otherwise encouraging findings and could weigh on how regulators, clinicians, and payers interpret the magnitude of Galleri’s clinical impact.

Complex Stage Distribution Clouds Interpretation

Investigators reported more Stage II cancers than expected and no clear reduction in Stage III, which complicated the composite Stage III plus IV endpoint. To clarify these mixed stage‑shift patterns, the team plans six to twelve additional months of follow‑up, delaying definitive conclusions and potentially slowing guideline and payer decisions.

Regulatory and Payer Scrutiny Likely

With a PMA now filed but a missed primary endpoint in a headline trial, management expects ongoing discussions with FDA and Medicare authorities. The possibility of advisory committee review and heightened focus on clinical utility adds uncertainty around the ultimate label, coverage terms, and speed of adoption if Galleri gains approval.

Operating Losses Remain Meaningful

Even with better gross profit trends, Grail remains deeply loss‑making, posting an adjusted EBITDA loss of $71.8 million in Q4 and $320.6 million for the year. Net loss reached $99.2 million for the quarter and $408.4 million for 2025, an improvement versus prior periods but still a substantial cash drain that investors must factor into valuation.

Development Services Revenue Under Pressure

The company’s development services revenue declined sharply, falling 49% year over year to $8.6 million for 2025, including just $1.3 million in the fourth quarter. Management suggested this reflects lower demand or a shift in revenue mix, underscoring Grail’s increasing reliance on Galleri’s commercial performance rather than legacy service contracts.

Future Illumina Royalties Threaten Margins

A supply agreement with Illumina includes royalty payments that are currently suspended through the end of 2026 but will resume thereafter at an expected high single‑digit percentage of oncology net sales. Management cautioned that this structure will pressure gross margins starting in 2027, reinforcing the need to drive scale efficiencies and pricing discipline.

Need for Further Data Maturation

To fully understand Galleri’s impact on cancer stage at diagnosis, Grail and its partners will extend follow‑up in the NHS‑Galleri study by six to twelve months. This delay pushes back the timing of key readouts that could shape medical guidelines and payer coverage, leaving investors in a holding pattern on the ultimate clinical and commercial upside.

Guidance and Outlook Signal Measured Confidence

For 2026, Grail reiterated expectations for Galleri sales growth of 22% to 32% and capped cash burn at no more than $300 million, anchored by its roughly $904 million cash balance. Management reminded investors of the anticipated 12‑month FDA review clock, highlighted improving gross profits and EBITDA trends, and reaffirmed its long‑term margin ambitions despite looming royalty headwinds.

Grail’s earnings call painted a picture of a company with strong commercial traction and a growing clinical evidence base, but also with unresolved scientific questions and an unprofitable financial profile. For investors, the story hinges on upcoming regulatory decisions, maturing NHS‑Galleri data, and the company’s ability to convert early adoption into sustainable, margin‑accretive growth.